WO2025162492 - LINKER, LIGAND-DRUG CONJUGATE AND MEDICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/162492
Publication Date
07.08.2025
International Application No.
PCT/CN2025/075857
International Filing Date
05.02.2025
Title **
[English]
LINKER, LIGAND-DRUG CONJUGATE AND MEDICAL USE THEREOF
[French]
LIEUR, CONJUGUÉ LIGAND-MÉDICAMENT ET UTILISATION MÉDICALE ASSOCIÉE
[Chinese]
一种连接子、配体-药物偶联物及其医药用途
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
SUN, Yingjie
JIAO, Jiao
CUI, Menghan
WANG, Jiaxing
CHE, Liming
Priority Data
202410116532.5
29.01.2024
CN
202410564053.X
08.05.2024
CN
202411388187.7
08.10.2024
CN
202411429922.4
14.10.2024
CN
202411783791.X
06.12.2024
CN
202411429096.3
14.10.2024
CN
202411795873.6
09.12.2024
CN
202411947010.6
27.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4236 | |
| EPO | Filing, Examination, Granting | 26535 | |
| Japan | Filing, Examination, Granting | 2670 | |
| South Korea | Filing, Examination, Granting | 3290 | |
| USA | Filing, Examination, Granting | 9740 |
Total:
46,471
Contact Us
Abstract[English]
A new drug linker, and a linker-drug system further prepared on the basis of the linker, a ligand-drug conjugate, an antibody conjugate drug, a pharmaceutical composition comprising the conjugate, and the medical use of the conjugate and the pharmaceutical composition. The new drug-linker system has a relatively high drug-antibody ratio (DAR) value, and the drug-ligand conjugate prepared on this basis has a relatively good tumor-inhibitory effect and has a relatively good clinical application prospect.[French]
L'invention concerne un nouveau lieur de médicament, et un système lieur-médicament préparé en outre sur la base du lieur, un conjugué ligand-médicament, un médicament conjugué d'anticorps, une composition pharmaceutique comprenant le conjugué, et l'utilisation médicale du conjugué et de la composition pharmaceutique. Le nouveau système de lieur de médicament a une valeur de rapport médicament-anticorps (DAR) relativement élevée, et le conjugué médicament-ligand préparé sur cette base a un effet inhibiteur de tumeur relativement bon et a une perspective d'application clinique relativement bonne.[Chinese]
一种新型药物连接子，以及基于连接子进一步制备的连接子-药物系统、配体药物偶联物、抗体偶联药物、包含所述偶联物的药物组合物、以及所述偶联物和药物组合物的医药用途。新型药物-连接子系统具备较高的药物抗体比率（DAR）值，在其基础上所制备的药物配体偶联物具有较好肿瘤抑制效果，具备较好的临床应用前景。